Why the study?
Does TEVAR improve early mortality and morbidity compared to open surgery in patients with acute thoracic aortic disease?
Does TEVAR improve early mortality and morbidity compared to open surgery in patients with acute thoracic aortic disease?
TEVAR offers a promising, less invasive alternative to open surgery for acute thoracic aortic disease, particularly benefiting high-risk patients by lowering early mortality and morbidity.
Thoracic endovascular aortic repair (TEVAR) has become an alternative treatment option for acute thoracic aortic disease. This review focuses on current endovascular treatment of acute thoracic aortic disease and future directions of TEVAR. TEVAR is a promising alternative approach to open surgery, with lower early mortality and morbidity rates, especially in high-risk cohorts. Furthermore, with accumulating experience and improving device technology and imaging modalities, TEVAR has become safer and has potential to expand treatment options to include ascending and arch pathologies.
No takes yet. Share an insight, caveat, or question.
Bombien et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: